ProShares Ultra Nasdaq Biotechnology (BIB)

Add to Watchlists Create an Alert
98.23 -2.97  -2.93% NASDAQ Sep 15, 4:59PM BATS Real time Currency in USD
View Full Chart
BIB Price Chart

BIB Description

ProShares Ultra Nasdaq Biotechnology is a long-short equity fund managed by ProShares that tracks the NASDAQ Biotechnology TR USD index and has 339.78M USD assets under management. It has a Prospective PE Ratio of 27.17 and a Prospective Price to Book Value of 6.504. The fund has a net expense ratio of 0.95%, turns over its positions 26.00% per year, and is traded on the NASDAQ.

Benchmark Index: NASDAQ Biotechnology TR USD

BIB Key Info

Expense Ratio (5-31-14) 0.95%
Assets Under Management (9-12-14) 339.78M
30-Day Average Volume (9-12-14) 193101.4
Net Asset Value (9-12-14) 101.43
Discount or Premium to NAV (9-12-14) -0.23%
Turnover Ratio (5-31-14) 26.00%

BIB Asset Allocation

Type % Net % Long % Short
Cash -99.31% 24.90% 124.2%
Stock 172.7% 173.3% 0.66%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 26.64% 26.64% 0.00%
As of June 30, 2014

BIB Region Exposure

Americas 94.34%
North America 94.34%
Latin America 0.00%
Greater Europe 5.59%
United Kingdom 1.65%
Europe Developed 3.94%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.07%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.07%
Market Classification
% Developed Markets 99.93%
% Emerging Markets 0.07%
As of June 30, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

BIB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 0.00%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of June 30, 2014

BIB Stock Market Capitalization

Giant --
Large --
Medium --
Small --
Micro --
As of June 30, 2014
View More Holdings

BIB Top 10 Holdings

Name % Weight Price Chg %
Nasdaq Biotechnology Index Swap Ubs Ag 58.87% -- --
Nasdaq Biotechnology Index Swap Credit Suisse International 19.23% -- --
Ishares Biotech (Ibb) Swap Deutsche Bank Ag 18.42% -- --
Nasdaq Biotechnology Index Swap Deutsche Bank Ag 9.10% -- --
Nasdaq Biotechnology Index Swap Bank Of America, Na 8.38% -- --
Celgene Corp 6.29% 89.46 -2.25%
Ishares Biotech (Ibb) Swap Bank Of America, Na 5.78% -- --
Gilead Sciences Inc 5.72% 100.96 -2.60%
Amgen Inc 5.72% 137.97 +0.06%
Biogen Idec Inc 5.53% 320.11 -1.01%
As of June 30, 2014
Get Quote for
Advertisement

BIB Risk Info

Beta 1.920
Max Drawdown (4-6-10 to 9-12-14) 41.44%
30 Day Average Volatility 33.40%

BIB Fundamentals

Dividend Yield TTM (9-15-14) 0%
Dividend Yield (Prospective) 0.26%
PE Ratio (Prospective) 27.17
PS Ratio (Prospective) 7.026
Price to Book Value (Prospective) 6.504
ROE --
ROA --
Number of Holdings 130.00
As of June 30, 2014

BIB Growth Estimates

Forecasted 5 Yr Earnings Growth 16.32%
Forecasted Book Value Growth 10.51%
Forecasted Cash Flow Growth 14.46%
Forecasted Earnings Growth 25.09%
Forecasted Revenue Growth 13.02%
As of June 30, 2014

BIB Performance

  Returns Total Returns
1M 10.69% 10.69%
3M 14.00% 14.00%
6M 0.01% 0.01%
1Y 55.62% 55.62%
3Y 577.4% 577.4%
5Y -- --
As of Sept. 12, 2014

BIB Flows

1M -48.14M
3M -70.38M
6M -84.99M
YTD 41.58M
1Y 91.32M
3Y 145.28M
5Y --
As of Aug. 31, 2014
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Start My Free Trial"}}

Already a {{root.upsell.info.tier_name}} Member? Sign in here.